Samira Zeynalova - Concepedia

Author

Samira Zeynalova

Also Known As

S Steidl, S Zeynalova, S. Zeynalova, S.R. Zeynalova, Samira Zeynalova, Solmaz Zeynalova, for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

117

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Leipzig University Saarland University University Hospital Leipzig Max Planck Institute for Human Cognitive and Brain Sciences Asklepios Klinik St. Georg

About

Samira Zeynalova is an author at Leipzig University specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	988
2	Health Sciences	5	5	180
3	Public Health	4	4	99
4	Engineering	1	1	37
5	Social Sciences	1	1	23

Samira Zeynalova

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Norbert Schmitz, Samira Zeynalova, Maike Nickelsen, Journal of Clinical Oncology	2016	427
CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Volkmar Boehme, Norbert Schmitz, Samira Zeynalova, Blood	2009	306
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Volkmar Boehme, Samira Zeynalova, Marita Kloess, Annals of Oncology Neuro-oncologyLymphoid NeoplasiaLymphoma Study GroupPathologyNeurology	2006	274
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL Carsten Müller, Niels Murawski, Martin H. J. Wiesen, Blood	2012	233
Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Wolfram Klapper, H. Stoecklein, Samira Zeynalova, Leukemia Hematological MalignancyLymphoid NeoplasiaStructural AberrationsOncologyLymphoma Study Group	2008	175
Suboptimal dosing of rituximab in male and female patients with DLBCL Michael Pfreundschuh, Carsten Müller, Samira Zeynalova, Blood	2013	139
Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement Gerhard Held, Samira Zeynalova, Niels Murawski, Journal of Clinical Oncology	2013	115
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group Norbert Schmitz, Samira Zeynalova, Ulrich Kaiser, Annals of Oncology Neuro-oncologyLymphoid NeoplasiaAggressive B-cell LymphomaMabthera International TrialPathology	2011	105
Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group Michael Pfreundschuh, Viola Poeschel, Samira Zeynalova, Journal of Clinical Oncology	2014	86
Cohort Profile: The LIFE-Adult-Study Christoph Engel, Kerstin Wirkner, Samira Zeynalova, International Journal of Epidemiology	2022	77

Page 1